Cytokinetics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cytokinetics and other ETFs, options, and stocks.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. 

CEO
Robert I. Blum
CEORobert I. Blum
Employees
498
Employees498
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
1997
Founded1997
Employees
498
Employees498

CYTK Key Statistics

Market cap
4.80B
Market cap4.80B
Price-Earnings ratio
-7.64
Price-Earnings ratio-7.64
Dividend yield
Dividend yield
Average volume
2.05M
Average volume2.05M
High today
$40.46
High today$40.46
Low today
$37.80
Low today$37.80
Open price
$38.46
Open price$38.46
Volume
1.39M
Volume1.39M
52 Week high
$68.44
52 Week high$68.44
52 Week low
$32.74
52 Week low$32.74

CYTK News

Benzinga 12h
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday
TipRanks 2d
Top Executive Sells Cytokinetics Stock in a Major Move!

New insider activity at Cytokinetics ( (CYTK) ) has taken place on April 23, 2025. Fady Ibraham Malik, the Executive Vice President of Research & Development a...

TipRanks 4d
Cytokinetics reiterated as top pick at H.C. Wainwright, Camzyos updates positive

Recent label updates for Bristol Myers’ (BMY) Camzyos should read positively for obstructive hypertrophic cardiomyopathy patients and physicians, as they could...

Analyst ratings

87%

of 23 ratings
Buy
87%
Hold
13%
Sell
0%

More CYTK News

TipRanks 4d
Cytokinetics Hold Rating: Competitive Challenges and Market Dynamics

Jason Zemansky, an analyst from Bank of America Securities, maintained the Hold rating on Cytokinetics (CYTK – Research Report). The associated price target rem...

TipRanks 6d
Insider Moves: Cytokinetics, Bj’s, Gran Tierra, PBF, Immunovant

Insiders have been trading these 5 stocks: ((CYTK)), ((BJ)), ((GTE)), ((PBF)) and ((IMVT)). Here is a breakdown of their recent trades and their value. In a no...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.